bms-863233
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2009 (NCT00838890)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
CDC7 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12- Mol. weight
- 289.72 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3544944 ↗
- ChEMBLCHEMBL3544943 ↗
Also known as
- bms-863233
- bms-863233
- bms-863233
- bms-863233
- xl-413
- xl-413
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00886782 | Phase 1/Phase 2 (Phase 2) | May 1, 2009 | Bristol-Myers Squibb, Exelixis |
| NCT00838890 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2009 | Bristol-Myers Squibb, Exelixis |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 2 | 2 | 1 | 2009 |
| Exelixis | For profit | 2 | 0 | 1 | 2009 |
2 organizations
Page 1 / 1